Literature DB >> 9584338

Pharmacological inhibition of leukotriene actions.

F Engels1, F P Nijkamp.   

Abstract

Leukotrienes represent a group of lipid mediators that play a very important role in a wide variety of pathological conditions. The presence of leukotrienes in inflammatory sites has been extensively documented, and accordingly research efforts have been directed towards the development of drugs that interfere with the formation or effects of leukotrienes. Although clinical application of such drugs has been disappointing in the past, recent discoveries of more potent and selective drugs seem to be promising. This review attempts to highlight some of these exciting developments.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9584338     DOI: 10.1023/a:1008698027211

Source DB:  PubMed          Journal:  Pharm World Sci        ISSN: 0928-1231


  59 in total

Review 1.  Biology and pathophysiology of leukotrienes.

Authors:  C Denzlinger
Journal:  Crit Rev Oncol Hematol       Date:  1996-07       Impact factor: 6.312

Review 2.  Inhibition of allergic and non-allergic inflammation by phospholipase A2 inhibitors.

Authors:  U Tibes; A Vondran; E Rodewald; W G Friebe; W Schäfer; W Scheuer
Journal:  Int Arch Allergy Immunol       Date:  1995 May-Jun       Impact factor: 2.749

3.  Morelloflavone, a novel biflavonoid inhibitor of human secretory phospholipase A2 with anti-inflammatory activity.

Authors:  B Gil; M J Sanz; M C Terencio; R Gunasegaran; M Payá; M J Alcaraz
Journal:  Biochem Pharmacol       Date:  1997-03-07       Impact factor: 5.858

4.  Comparative effects of inhaled leukotriene C4, leukotriene D4, and histamine in normal human subjects.

Authors:  N C Barnes; P J Piper; J F Costello
Journal:  Thorax       Date:  1984-07       Impact factor: 9.139

5.  Effect of a leukotriene antagonist, ONO-1078, on bronchial hyperresponsiveness in patients with asthma.

Authors:  M Fujimura; S Sakamoto; Y Kamio; T Matsuda
Journal:  Respir Med       Date:  1993-02       Impact factor: 3.415

6.  The potent and selective sulfidopeptide leukotriene antagonist, SK&F 104353, inhibits aspirin-induced asthma.

Authors:  P E Christie; C M Smith; T H Lee
Journal:  Am Rev Respir Dis       Date:  1991-10

7.  The effect of inhibition of 5-lipoxygenase by zileuton in mild-to-moderate asthma.

Authors:  E Israel; P Rubin; J P Kemp; J Grossman; W Pierson; S C Siegel; D Tinkelman; J J Murray; W Busse; A T Segal; J Fish; H B Kaiser; D Ledford; S Wenzel; R Rosenthal; J Cohn; C Lanni; H Pearlman; P Karahalios; J M Drazen
Journal:  Ann Intern Med       Date:  1993-12-01       Impact factor: 25.391

8.  The leukotriene-receptor antagonist MK-0679 blocks airway obstruction induced by inhaled lysine-aspirin in aspirin-sensitive asthmatics.

Authors:  B Dahlén; M Kumlin; D J Margolskee; C Larsson; H Blomqvist; V C Williams; O Zetterström; S E Dahlén
Journal:  Eur Respir J       Date:  1993-07       Impact factor: 16.671

9.  Effect of the 5-lipoxygenase inhibitor ZD2138 on allergen-induced early and late asthmatic responses.

Authors:  S M Nasser; G S Bell; R J Hawksworth; K E Spruce; R MacMillan; A J Williams; T H Lee; J P Arm
Journal:  Thorax       Date:  1994-08       Impact factor: 9.139

10.  Effect of SC-41930, a potent selective leukotriene B4 receptor antagonist, in the guinea pig model of middle ear inflammation.

Authors:  Y Sutbeyaz; B Yakan; H Ozdemir; M Karasen; F Doner; I Kufrevioglu
Journal:  Ann Otol Rhinol Laryngol       Date:  1996-06       Impact factor: 1.547

View more
  1 in total

Review 1.  Montelukast: a review of its therapeutic potential in asthma in children 2 to 14 years of age.

Authors:  Richard B R Muijsers; Stuart Noble
Journal:  Paediatr Drugs       Date:  2002       Impact factor: 3.022

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.